European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Blood

Volumn 112, Issue 12, 2008, Pages 4437-4444

  Marin, David ^a,b   Milojkovic, Dragana ^a   Olavarria, Eduardo ^a   Khorashad, Jamshid S ^a   De Lavallade, Hugues ^a   Reid, Alistair G ^a   Foroni, Letizia ^a   Rezvani, Katayoun ^a   Bua, Marco ^a   Dazzi, Francesco ^a   Pavlu, Jiri ^a   Klammer, Matthias ^a   Kaeda, Jaspal S ^a   Goldman, John M ^a   Apperley, Jane F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELIABILITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ALGORITHM; DRUG RESISTANCE; EUROPE; EVALUATION; FACTUAL DATABASE; HEALTH CARE PLANNING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149396984     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-162388     Document Type: Article

References (21)

1. Tura S, Baccarani M. Alpha-interferon in the treatment of chronic myeloid leukemia: the Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 1995;85:2999-3002.
2. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
3. Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006;355:2408-2417.
4. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3363.
5. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60.
6. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107:4171-4176.
7. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
8. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol. 2002; 107:64-75.
9. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005; 19:507-512.
10. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
11. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
12. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837-845.
13. Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72:294-298.
14. Vardiman JW, Pierre RV, Thiele J, et al. Chronic myelogenous leukaemia. In: Jaffe SE, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:20-26.
15. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 2003;88:260-267.
16. Khorashad J, de Lavallade H, Apperley J, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008; 26:4806-4813.
17. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354: 2542-2551.
18. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309.
19. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354: 2531-2541.
20. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111:1834-1839.
21. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112:516-518.